CLEVELAND BIOLABS INC Form 10QSB May 15, 2007

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 10-QSB

	/A / 1	\ \
1	Mark	one)

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended March 31, 2007

or

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

For the transition period from ______ to _____.

Commission File Number 001-12465

CLEVELAND BIOLABS, INC. (Exact name of small business issuer as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation or organization) 20-0077155 (I.R.S. Employer Identification No.)

11000 Cedar Ave., Suite 290 CLEVELAND, OHIO 44106 (Address of principal executive offices and zip code)

> (216) 229-2251 (Issuer's telephone number)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES x NO "

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES " NO x

Edgar Filing: CLEVELAND BIOLABS INC - Form 10QSB

As of March 31, 2007 there were 11,889,099 shares of registrant's common stock, \$0.005 par value

Transitional Small Business Disclosure Format (Check One): YES " NO x

CLEVELAND BIOLABS INC 10-QSB 05/15/2007

TABLE OF CONTENTS

PAGE

PART I - FINANCIAL INFORMATION

ITEM 1:	Financial Statements	
	Balance Sheets as of March 31, 2007 and December 31, 2006	2-3
	Statements of Operations For Three Months Ended March 31, 2007 and 2006	4
	Statements of Cash Flows For Three Months Ended March 31, 2007 and 2006	5
	Statement of Stockholders' Equity January 1, 2006 to December 31, 2007 and to March 31, 2007	6
	Notes to Condensed Consolidated Financial Statements	9
ITEM 2:	Management's Discussion and Analysis of Financial Conditions and Results of Operations	18
ITEM 3:	Controls and Procedures	29
PART II - OT	HER INFORMATION	
ITEM 1:	Legal Proceedings	30
ITEM 2:	Unregistered Sales of Equity Securities and Use of Proceeds	30
ITEM 3:	Defaults Upon Senior Securities	30
ITEM 4:	Submission of Matters to a Vote of Securities Holders	30
ITEM 5:	Other Information	30
ITEM 6:	Exhibits	31
Signatures		32

In this report, "Cleveland BioLabs," "CBL," "we," "us" and "our" refer to Cleveland BioLabs, Inc. "common stock" refers to Cleveland BioLabs, Inc.'s common stock, par value \$0.005 per share.

Edgar Filing: CLEVELAND BIOLABS INC - Form 10QSB

CLEVELAND BIOLABS, INC.

BALANCE SHEETS

March 31, 2007 (un	naudited) and De	cember 31, 2006			
		March 31		December 31	
		2007		2006	
<u>ASSETS</u>	(unaudited)				
CURRENT ASSETS					
Cash and equivalents	\$	11,968,017	\$	3,061,993	
Short-term investments		18,699,965		1,995,836	
Accounts receivable:					
Trade		214,048		159,750	
Interest		53,255		42,479	
Notes Receivable - Orbit Brands		300,000		50,171	
Other prepaid expenses		512,969		434,675	
Total current assets		31,748,254		5,744,904	
EQUIPMENT					
Computer equipment		143,426		132,572	
Lab equipment		348,730		347,944	
Furniture		65,087		65,087	
		557,243		545,603	
Less accumulated depreciation		169,677		142,011	
-		387,566		403,592	
OTHER ASSETS					
Intellectual Property		346,170		252,978	
Deposits		15,055		15,055	
		361,225		268,033	
TOTAL ASSETS	\$	32,497,045	\$	6,416,529	
2					

Edgar Filing: CLEVELAND BIOLABS INC - Form 10QSB

CLEVELAND BIOLABS, INC.

BALANCE SHEETS

March 31, 2007 (unaudited)	and December 31, 2006
	Moroh 21

LIABILITIES AND STOCKHOLDERS' EQUITY		March 31 2007 (unaudited)		December 31 2006	
CURRENT LIABILITIES					
Accounts payable:					
Trade	\$	1,111,836	\$	644,806	
Accrued expenses		227,435		128,569	
Total current liabilities		1,339,271		773,375	
LONG-TERM LIABILITIES					
Milestone payables		300,000		50,000	
Total long-term liabilities		300,000		50,000	
STOCKHOLDERS' EQUITY					
Series B convertible preferred stock, \$.005 par value					
Authorized - 10,000,000 shares at March 31, 2007					
and December 31, 2006		22,895		-	
Issued and outstanding 4,579,010 and 0					
shares at March 31, 2007 and December 31, 2006,					
respectively					
Additional paid-in capital		28,849,983		-	